斯鲁利单抗致老年结肠肿瘤患者多器官免疫性损伤1例分析

doi:10.19803/j.1672-8629.20241005

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (10): 1165-1167.
DOI: 10.19803/j.1672-8629.20241005

斯鲁利单抗致老年结肠肿瘤患者多器官免疫性损伤1例分析

李小梅, 王洪贵^*, 孙嘉婧

四川省成都市都江堰市人民医院,四川成都 611830

收稿日期:2024-12-20 出版日期:2025-10-15 发布日期:2025-10-20
通讯作者: ^*王洪贵,男,硕士,主任药师,医院药学。E-mail: 71700330@qq.com
作者简介:李小梅,女,硕士,副主任药师,临床药学。

One Case of Multi-Organ Immune Injury Caused by Serplulimab in an Elderly Patient with Colon Tumor

LI Xiaomei, WANG Honggui^*, SUN Jiajing

Dujiangyan People's Hospital, Chengdu Sichuan 611830, China

Received:2024-12-20 Online:2025-10-15 Published:2025-10-20

摘要/Abstract

摘要： 目的探讨斯鲁利单抗致多器官免疫性损伤的不良反应,为临床安全用药提供参考。方法对1例斯鲁利单抗致老年结肠肿瘤患者多器官免疫性损伤的病例进行分析,并结合相关文献进行归纳和总结。结果根据患者的临床表现、实验室检查及用药时间关联性,斯鲁利单抗致多器官免疫性损伤为很可能,经停用斯鲁利单抗,给予糖皮质激素治疗后患者好转出院,但因患者院外未遵医嘱用药及未监测不良反应等最终导致不良反应进展。结论免疫检查点抑制剂致多器官免疫性损伤发生率较低,但致死率较高。临床在应用斯鲁利单抗治疗前加强风险评估,用药期间严密监测,注意斯鲁利单抗致多器官免疫性损伤的风险。

关键词: 斯鲁利单抗, 心肌炎, 重症肌无力, 肌炎, 程序性死亡受体1, 免疫检查点抑制剂

Abstract: Objective To investigate such adverse reactions as multi-organ immune injury induced by serplulimab, and to provide a reference for safe clinical practice. Methods One case of multi-organ immune injury induced by serplulimab in an elderly patient with colon tumors was analyzed, and a summary was made after literature review. Results Based on the patient's clinical manifestations, results of laboratory tests, and the temporal association with drug administration,the patient's multi-organ immune injury was considered to have been caused by serplulimab. The patient improved and was discharged after glucocorticoid therapy. However, the adverse reactions progressed because the patient failed to take the prescribed drugs or monitor for adverse reactions after discharge. Conclusion The incidence of ICIs-associated multi-organ immune injury is relatively low, but the fatality is exceedingly high. Clinicians should assess the risk before administering serplulimab, closely monitor patients during treatment, and remain alert to the risk of serplulimab-induced multi-organ immune injury.

Key words: Serplulimab, Myocarditis, Myasthenia gravis, Myositis, PD-1, ICIs

中图分类号:

R969.3

李小梅, 王洪贵, 孙嘉婧. 斯鲁利单抗致老年结肠肿瘤患者多器官免疫性损伤1例分析[J]. 中国药物警戒, 2025, 22(10): 1165-1167.

LI Xiaomei, WANG Honggui, SUN Jiajing. One Case of Multi-Organ Immune Injury Caused by Serplulimab in an Elderly Patient with Colon Tumor[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1165-1167.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20241005

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I10/1165

参考文献

[1] SHAO T, ZHAO M, LIANG L, et al.Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: a Cost-Effectiveness Analysis to Inform Drug Pricing[J].Bio Drugs, 2023, 37(3): 421-432.
[2] TIAN ZX, XIA F, ZHANG SC, et al.A Case of Immune Myocarditis Caused by Serplulimab Combined with Axitinib[J].Herald of Medicine(医药导报), 2024, 43(9): 1496-1498.
[3] LUO ZL.A Case Report: Immune-Related Myocarditis Caused by Pulmonary Neuroendocrine Tumor Treated by Serplulimab[J]. Chin J Hosp Pharm.(中国医院药学杂志), 2025, 45(2): 238-240.
[4] WANG F, GONG XL, GENG HY, et al.A Case of Asymptomatic Immune Checkpoint Inhibitor Associated Myocarditis and Myositis[J]. Chin J Cardiol,(中华心血管病杂志), 2022, 50(11): 1103-1105.
[5] ZOU C, WU F, LIN L, et al.A Case of Pre-Myasthenia Gravis Crisis Complicated with Myocarditis, Myositis and Liver Dysfunction Caused by Immune Checkpoint Inhibitors[J]. Journal of Clinical Neurology, 2025, 38(3): 232-233.
[6] LIU YJ, MA SS, ZHENG JB, et al.A Case of Immune Myocarditis and Myositis Caused by Immune Checkpoint Inhibitors[J]. Journal of China-Japan Friendship Hospital(中日友好医院学报), 2021, 35(4): 251.
[7] ZHANG JL, YUE XT, WANG CJ, et al.Three Cases of Myasthenia Gravis Caused by Immune Checkpoint Inhibitors[J]. Journal of Shandong First Medical University & Shandong Academy of Medical Sciences[山东第一医科大学(山东省医学科学院)学报] , 2024, 45(9): 567-570.
[8] HAN L, WANG W, REN JY, et al.Immune Checkpoint Inhibitor-Associated Myocarditis, Myasthenia Gravis and Myositis: a Case Report[J]. Chin J Cardiovasc Med(中国心血管杂志), 2024, 29(2): 122-124.
[9] Chinese Society of Clinical Oncology. Guidelines for the Management of Toxicity Associated with Immune Checkpoint Inhibitors(免疫检查点抑制剂相关的毒性管理指南)[M]. Beijing: People's Medical Publishing House, 2021.
[10] ZHOU YW, ZHU YJ, WANG MN, et al.Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management[J]. Front Pharmacol, 2019, 10: 1350.
[11] YIN YS, WU YP, LI Y, et al.Analysis on the Risk of Myocarditis Caused by PD-1/PD-L1 Inhibitors Based on FDA Adverse Event Reporting System[J]. Clinical Medication Journal(临床药物治疗杂志), 2023, 21(11): 76-80.
[12] WANG Y, CHEN HY, LIN JY, et al.Recommendations for Clinical Diagnosis and Treatment of Immune Checkpoint Inhibitors-Associated Myocarditis[J]. Chin J Clin Med(中国临床医学), 2023, 30(2): 368-391.
[13] Committee of Neoplastic Supportive-Care, China Anti-Cancer Association, Cancer Clinical Chemotherapy Committee, China Anti-Cancer Association. Chinese Expert Consensus on Diagnosis and Treatment of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors(2022 Edition)[J]. Chin J Oncol(中华肿瘤杂志), 2022, 44(9): 935-941.
[14] GUMMI RR, KUKULKA NA, DEROCHE CB, et al.Factors Associated with Acute Exacerbations of Myasthenia Gravis[J]. Muscle Nerve, 2019, 60(6): 693-699.
[15] WU DX, ZHANG Y, SHI YF, et al.Immune Checkpoint Inhibitor-Associated Myositis, Myocarditis and Myasthenia Gravis Overlap Syndrome Based on the US FDA Adverse Event Reporting System[J]. Central South Pharmacy(中南药学), 2023, 21(8): 2232-2237.

斯鲁利单抗致老年结肠肿瘤患者多器官免疫性损伤1例分析

One Case of Multi-Organ Immune Injury Caused by Serplulimab in an Elderly Patient with Colon Tumor

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.
[2]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[3]	朱磊, 张弦, 汪瑞妍, 李颖. 447例替雷利珠单抗注射液不良反应报告分析[J]. 中国药物警戒, 2025, 22(6): 649-653.
[4]	梁方林, 陈玲园, 胡丹荔, 韦玲云, 韦铁猛, 张发恩, 韦亚娜. 120例肝癌患者使用替雷利珠单抗致免疫相关不良事件分析[J]. 中国药物警戒, 2025, 22(6): 659-663.
[5]	张云惠, 陈浩云, 钟陆华, 房财富, 黄焕均, 郭晨晨, 董心仪, 石凤, 梁蔚婷. 159例免疫检查点抑制剂不良反应分析[J]. 中国药物警戒, 2025, 22(4): 442-446.
[6]	陈玲彬, 黄志雄, 郑彩琳, 吴金能, 陈洲. 基于美国FAERS数据库的奥希替尼致肌肉毒性不良事件信号分析[J]. 中国药物警戒, 2025, 22(4): 447-451.
[7]	孟现奇, 朱伟南, 张印印. 160例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(10): 1148-1153.
[8]	刘楠楠, 席雅琳, 陈喆. 卡度尼利单抗致肾上腺皮质功能减退1例分析[J]. 中国药物警戒, 2025, 22(1): 109-112.
[9]	孙熙木, 周涵, 李雁铭, 郭鹏, 聂晓璐. 基于美国FAERS数据库的免疫检查点抑制剂相关血小板减少症信号挖掘与分析[J]. 中国药物警戒, 2025, 22(1): 23-28.
[10]	张健, 张伶俐, 李歆. 424例替雷利珠单抗致免疫相关不良事件分析[J]. 中国药物警戒, 2024, 21(4): 435-439.
[11]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[12]	汪滢, 黄珊, 沈钦勇, 连霞, 常颖, 江彦, 林兵, 黄爱文. 79例替雷利珠单抗相关不良反应分析[J]. 中国药物警戒, 2024, 21(10): 1148-1153.
[13]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[14]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[15]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.